Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $17.11, for a total value of $85,550.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Sangamo Therapeutics Inc (NASDAQ SGMO) opened at $17.15 on Friday. Sangamo Therapeutics Inc has a one year low of $3.35 and a one year high of $18.69. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64. The firm has a market capitalization of $1,450.00, a PE ratio of -24.86 and a beta of 3.15.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company had revenue of $11.81 million during the quarter, compared to the consensus estimate of $10.37 million. During the same period last year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 333.0% on a year-over-year basis. equities research analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Sangamo Therapeutics by 12.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after purchasing an additional 384,031 shares in the last quarter. State Street Corp raised its stake in shares of Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock worth $16,441,000 after purchasing an additional 636,296 shares in the last quarter. RA Capital Management LLC purchased a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth about $11,000,000. Northern Trust Corp raised its stake in shares of Sangamo Therapeutics by 4.9% in the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after acquiring an additional 44,656 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Sangamo Therapeutics by 93.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 693,300 shares of the biopharmaceutical company’s stock valued at $10,400,000 after acquiring an additional 335,595 shares in the last quarter. 64.33% of the stock is owned by institutional investors.
A number of brokerages have commented on SGMO. BidaskClub lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays assumed coverage on Sangamo Therapeutics in a research note on Wednesday, November 22nd. They set an “overweight” rating and a $20.00 price target for the company. Wedbush reaffirmed a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Piper Jaffray Companies set a $25.00 price target on Sangamo Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research note on Wednesday, November 15th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $18.83.
COPYRIGHT VIOLATION NOTICE: “Edward R. Conner Sells 5,000 Shares of Sangamo Therapeutics Inc (SGMO) Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/12/edward-r-conner-sells-5000-shares-of-sangamo-therapeutics-inc-sgmo-stock.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.